Clinical Trial Update: Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Magtrace for delayed sentinel lymph node biopsy in Ductal Carcinoma in Situ has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ductal Carcinoma in Situ

Drugs mentioned

• Magtrace

Snippet

Sponsor: University of Florida | Conditions: Ductal Carcinoma in Situ | Phase 2 | Status: WITHDRAWN